{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:12:56Z","timestamp":1791364376971,"version":"4.3.1"},"reference-count":38,"publisher":"Georg Thieme Verlag KG","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rofo"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ovarian cancer remains a significant cause of mortality among women, largely due to challenges in early detection. Current screening strategies, including transvaginal ultrasound and CA125 testing, have limited sensitivity and specificity, particularly in asymptomatic women or those with early-stage disease. The European Society of Gynaecological Oncology, the European Society for Medical Oncology, the European Society of Pathology, and other health organizations currently do not recommend routine population-based screening for ovarian cancer due to the high rates of false-positives and the absence of a reliable early detection method.<\/jats:p>\n                  <jats:p>This review examines existing ovarian cancer screening guidelines and explores recent advances in diagnostic technologies including radiomics, artificial intelligence, point-of-care testing, and novel detection methods.<\/jats:p>\n                  <jats:p>Emerging technologies show promise with respect to improving ovarian cancer detection by enhancing sensitivity and specificity compared to traditional methods. Artificial intelligence and radiomics have potential for revolutionizing ovarian cancer screening by identifying subtle diagnostic patterns, while liquid biopsy-based approaches and cell-free DNA profiling enable tumor-specific biomarker detection. Minimally invasive methods, such as intrauterine lavage and salivary diagnostics, provide avenues for population-wide applicability. However, large-scale validation is required to establish these techniques as effective and reliable screening options.<\/jats:p>","DOI":"10.1055\/a-2589-5696","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T18:33:52Z","timestamp":1748025232000},"page":"1395-1404","source":"Crossref","is-referenced-by-count":4,"title":["Ovarian Cancer Screening: Recommendations and Future Prospects"],"prefix":"10.1055","volume":"197","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3337-6816","authenticated-orcid":false,"given":"Selina","family":"Chiu","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London, London, United Kingdom of Great Britain and Northern Ireland"},{"name":"Department of Gynaecology Oncology, Imperial College Healthcare NHS Trust, London, United Kingdom of Great Britain and Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Staley","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Chelsea and Westminster Healthcare NHS Trust, London, United Kingdom of Great Britain and Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Jeevananthan","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Imperial College Healthcare NHS Trust, London, United Kingdom of Great Britain and Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Mascarenhas","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London, London, United Kingdom of Great Britain and Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Fotopoulou","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London, London, United Kingdom of Great Britain and Northern Ireland"},{"name":"Department of Gynaecology Oncology, Imperial College Healthcare NHS Trust, London, United Kingdom of Great Britain and Northern Ireland"},{"name":"Department of Gynaecology, Charit\u00e9, University Hospital Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rockall","sequence":"additional","affiliation":[{"name":"Department of Radiology, Imperial College Healthcare NHS Trust, London, United Kingdom of Great Britain and Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"ref3","doi-asserted-by":"publisher","first-page":"h4443","DOI":"10.1136\/bmj.h4443","article-title":"Diagnosis of ovarian cancer","volume":"351","author":"S Sundar","year":"2015","journal-title":"Bmj"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","article-title":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"397","author":"U Menon","year":"2021","journal-title":"The Lancet"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/s1470-2045(23)00335-2","article-title":"Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trial","volume":"24","author":"U Menon","year":"2023","journal-title":"Lancet Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"251s","DOI":"10.1016\/s0197-2456(00)00097-0","article-title":"The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status","volume":"21","author":"JK Gohagan","year":"2000","journal-title":"Control Clin Trials"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of Screening on Ovarian Cancer Mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial","volume":"305","author":"SS Buys","year":"2011","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Annals of Oncology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/aog.0000000000005211","article-title":"Executive Summary of the Ovarian Cancer Evidence Review Conference","volume":"142","author":"W Burke","year":"2023","journal-title":"Obstet Gynecol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1001\/jama.2017.21926","article-title":"Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement","volume":"319","author":"DC Grossman","year":"2018","journal-title":"Jama"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO\u2013ESMO\u2013ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"JA Ledermann","year":"2024","journal-title":"Annals of Oncology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/S1470-2045(24)00406-6","article-title":"Risk-prediction models in postmenopausal patients with symptoms of suspected ovarian cancer in the UK (ROCkeTS): a multicentre, prospective diagnostic accuracy study","volume":"25","author":"S Sundar","year":"2024","journal-title":"The Lancet Oncology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.5306\/wjco.v14.i2.40","article-title":"Hereditary cancer syndromes","volume":"14","author":"EN Imyanitov","year":"2023","journal-title":"World J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-020-00654-3","article-title":"BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases","volume":"13","author":"M Suszynska","year":"2020","journal-title":"Journal of Ovarian Research"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1200\/jco.2016.69.9330","article-title":"Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study","volume":"35","author":"AN Rosenthal","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1158\/1940-6207.Capr-19-0506","article-title":"A Systematic Review on Cost-effectiveness Studies Evaluating Ovarian Cancer Early Detection and Prevention Strategies","volume":"13","author":"G Sroczynski","year":"2020","journal-title":"Cancer Prev Res (Phila)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare9121740","article-title":"Online Health Information Seeking Behavior: A Systematic Review","volume":"9","author":"X Jia","year":"2021","journal-title":"Healthcare (Basel)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-17673-0","article-title":"Using online search activity for earlier detection of gynaecological malignancy","volume":"24","author":"JF Barcroft","year":"2024","journal-title":"BMC Public Health"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-037459","article-title":"Cancer Loyalty Card Study (CLOCS): protocol for an observational case\u2013control study focusing on the patient interval in ovarian cancer diagnosis","volume":"10","author":"HR Brewer","year":"2020","journal-title":"BMJ Open"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2196\/41762","article-title":"Association Between Purchase of Over-the-Counter Medications and Ovarian Cancer Diagnosis in the Cancer Loyalty Card Study (CLOCS): Observational Case-Control Study","volume":"9","author":"HR Brewer","year":"2023","journal-title":"JMIR Public Health Surveill"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2196\/37141","article-title":"Using Shopping Data to Improve the Diagnosis of Ovarian Cancer: Computational Analysis of a Web-Based Survey","volume":"9","author":"EH Dolan","year":"2023","journal-title":"JMIR Cancer"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e2203","DOI":"10.1002\/hsr2.2203","article-title":"Prediction of ovarian cancer using artificial intelligence tools","volume":"7","author":"SM Ayyoubzadeh","year":"2024","journal-title":"Health Sci Rep"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13244-020-00887-2","article-title":"Radiomics in medical imaging\u2014\u201chow-to\u201d guide and critical reflection","volume":"11","author":"JE van Timmeren","year":"2020","journal-title":"Insights into Imaging"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41698-024-00527-8","article-title":"Machine learning and radiomics for segmentation and classification of adnexal masses on ultrasound","volume":"8","author":"JF Barcroft","year":"2024","journal-title":"npj Precision Oncology"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s41747-021-00226-0","article-title":"A decision support system based on radiomics and machine learning to predict the risk of malignancy of ovarian masses from transvaginal ultrasonography and serum CA-125","volume":"5","author":"V Chiappa","year":"2021","journal-title":"European Radiology Experimental"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1158\/1940-6207.capr-11-0508","article-title":"Programmable Bio-Nano-Chip Systems for Serum CA125 Quantification: Toward Ovarian Cancer Diagnostics at the Point-of-Care","volume":"5","author":"A Raamanathan","year":"2012","journal-title":"Cancer Prevention Research"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s10544-023-00659-x","article-title":"Point-of-care testing: a disposable label-free electrochemical CA125 and HE4 immunosensors for early detection of ovarian cancer","volume":"25","author":"M Bilgi Kama\u00e7","year":"2023","journal-title":"Biomed Microdevices"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041256","article-title":"Urine CA125 and HE4 for the Detection of Ovarian Cancer in Symptomatic Women","volume":"15","author":"CE Barr","year":"2023","journal-title":"Cancers (Basel)"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1039\/c1lc20479c","article-title":"Integration of cell phone imaging with microchip ELISA to detect ovarian cancer HE4 biomarker in urine at the point-of-care","volume":"11","author":"S Wang","year":"2011","journal-title":"Lab on a Chip"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242115716","article-title":"Top-Down Proteomics of Human Saliva, Analyzed with Logistic Regression and Machine Learning Methods, Reveal Molecular Signatures of Ovarian Cancer","volume":"24","author":"F Scebba","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2024.101330","article-title":"Uterine washings as a novel method for early detection of ovarian cancer: Trials and tribulations","volume":"51","author":"TY Sia","year":"2024","journal-title":"Gynecologic Oncology Reports"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ygyno.2021.10.083","article-title":"A novel proteomic-based screening method for ovarian cancer using cervicovaginal fluids: A window into the abdomen","volume":"164","author":"RP Rocconi","year":"2022","journal-title":"Gynecologic Oncology"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13048-022-01068-z","article-title":"Can circulating cell free DNA be a promising marker in ovarian cancer? \u2013 a genome-scale profiling study in a single institution","volume":"16","author":"H Zhou","year":"2023","journal-title":"J Ovarian Res"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"5196","DOI":"10.1158\/1078-0432.ccr-23-1197","article-title":"OvaPrint\u2014A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer","volume":"29","author":"DN Buckley","year":"2023","journal-title":"Clinical Cancer Research"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2024.09.001","article-title":"Improving Specificity for Ovarian Cancer Screening Using a Novel Extracellular Vesicle\u2013Based Blood Test","author":"ES Winn-Deen","year":"2024","journal-title":"The Journal of Molecular Diagnostics"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"5553","DOI":"10.1200\/JCO.2024.42.16_suppl.5553","article-title":"Evaluation of a novel extracellular vesicle (EV) based ovarian cancer (OC) screening test in asymptomatic postmenopausal women","volume":"42","author":"B Manning","year":"2024","journal-title":"Journal of Clinical Oncology"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"c6839","DOI":"10.1136\/bmj.c6839","article-title":"Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group","volume":"341","author":"D Timmerman","year":"2010","journal-title":"Bmj"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1148\/radiol.2019191354","article-title":"Simple Adnexal Cysts: SRU Consensus Conference Update on Follow-up and Reporting","volume":"293","author":"D Levine","year":"2019","journal-title":"Radiology"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.230685","article-title":"O-RADS US v2022: An Update from the American College of Radiology\u2019s Ovarian-Adnexal Reporting and Data System US Committee","volume":"308","author":"LM Strachowski","year":"2023","journal-title":"Radiology"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"e1919896","DOI":"10.1001\/jamanetworkopen.2019.19896","article-title":"Ovarian-Adnexal Reporting Data System Magnetic Resonance Imaging (O-RADS MRI) Score for Risk Stratification of Sonographically Indeterminate Adnexal Masses","volume":"3","author":"I Thomassin-Naggara","year":"2020","journal-title":"JAMA Network Open"}],"container-title":["R\u00f6Fo - Fortschritte auf dem Gebiet der R\u00f6ntgenstrahlen und der bildgebenden Verfahren"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2589-5696.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T23:40:21Z","timestamp":1763509221000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2589-5696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":38,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,11,18]]},"published-print":{"date-parts":[[2025,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2589-5696","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1438-9029","1438-9010"],"issn-type":[{"value":"1438-9029","type":"print"},{"value":"1438-9010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]}}}